| |
Records |
Links |
|
Author |
European Monitoring Centre for Drugs and Drug Addiction |
|
| |
Title |
Workgroup on costs and cost-effectiveness of interventions : executive summary |
Type |
Report |
| |
Year |
2002 |
Publication |
|
Abbreviated Journal  |
|
|
| |
Volume |
|
Issue |
|
Pages |
5 |
|
| |
Keywords |
AOD use, abuse, and dependence; cost (economic); cost-effectiveness; prevention; viral hepatitis; hepatitis B; hepatitis C; international area; Europe |
|
| |
Abstract |
|
|
| |
Address |
|
|
| |
Corporate Author |
|
Thesis |
|
|
| |
Publisher |
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) |
Place of Publication |
Lisbon |
Editor |
|
|
| |
Language |
English |
Summary Language |
|
Original Title |
|
|
| |
Series Editor |
|
Series Title |
|
Abbreviated Series Title |
|
|
| |
Series Volume |
|
Series Issue |
|
Edition |
|
|
| |
ISSN |
|
ISBN |
|
Medium |
|
|
| |
Area |
|
Expedition |
|
Conference |
|
|
| |
Notes |
|
Approved |
no |
|
| |
Call Number |
50-e |
Serial |
50462 |
|
| Permanent link to this record |
| |
|
| |
|
Author |
European Monitoring Centre for Drugs and Drug Addiction |
|
| |
Title |
Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs |
Type |
Report |
| |
Year |
2003 |
Publication |
|
Abbreviated Journal |
|
|
| |
Volume |
|
Issue |
|
Pages |
122 |
|
| |
Keywords |
amphetamines; monitoring; risk assessment; designer drug; research chemical; report; Europe |
|
| |
Abstract |
The report assesses the risks of PMMA, especially in association with the already controlled substance PMA (para-methoxyamphetamine). PMMA, is an amphetamine-like substance very close to PMA, and is almost exclusively sold in tablet form in combination with the latter and consumed as ‘ecstasy’. It has been associated, in combination with PMA, with three deaths in the EU. PMMA is devoid of any therapeutic value. Further to the conclusions of the EMCDDA risk assessment, on 28 February 2002, the Council of the European Union adopted a unanimous decision defining the new synthetic drug PMMA (para-methoxymethylamphetamine) as a substance to be placed under control measures and criminal penalties in the EU Member States. |
|
| |
Address |
|
|
| |
Corporate Author |
|
Thesis |
|
|
| |
Publisher |
Office for Official Publications of the European Communities |
Place of Publication |
Luxemburg |
Editor |
|
|
| |
Language |
English |
Summary Language |
|
Original Title |
|
|
| |
Series Editor |
|
Series Title |
Risk assessments |
Abbreviated Series Title |
|
|
| |
Series Volume |
|
Series Issue |
|
Edition |
|
|
| |
ISSN |
1725-4485 |
ISBN |
92-9168-137-7 |
Medium |
|
|
| |
Area |
|
Expedition |
|
Conference |
|
|
| |
Notes |
|
Approved |
no |
|
| |
Call Number |
50-13429 |
Serial |
50464 |
|
| Permanent link to this record |
| |
|
| |
|
Author |
European Monitoring Centre for Drugs and Drug Addiction |
|
| |
Title |
Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs |
Type |
Report |
| |
Year |
2002 |
Publication |
|
Abbreviated Journal |
|
|
| |
Volume |
|
Issue |
|
Pages |
116 |
|
| |
Keywords |
ketamine; monitoring; risk assessment; designer drug; research chemical; report; Europe |
|
| |
Abstract |
Since the mid-1990s, ketamine – widely used in human and veterinary medicine for 30 years – has been surfacing as a recreational drug. Concern over ketamine centres on its unpredictability in producing ‘near-death’ experiences. The risk-assessment exercise was carried out in 2000 in the framework of the Joint action on new synthetic drugs. In March 2001, the EU Justice and Home Affairs Council adopted formal conclusions that Member States should monitor this drug closely. This publication records the findings and conclusions of the exercise. Among others, it draws together the various elements used to assess the substance including: the final risk-assessment report; contributions from Europol and the European Agency for the Evaluation of Medicinal Products; a review of pharmacotoxicological data; epidemiological evidence on the associated public-health risks and sociological and criminological evidence. |
|
| |
Address |
|
|
| |
Corporate Author |
|
Thesis |
|
|
| |
Publisher |
Office for Official Publications of the European Communities |
Place of Publication |
Luxembourg |
Editor |
|
|
| |
Language |
English |
Summary Language |
|
Original Title |
|
|
| |
Series Editor |
|
Series Title |
|
Abbreviated Series Title |
|
|
| |
Series Volume |
|
Series Issue |
|
Edition |
|
|
| |
ISSN |
1725-4485 |
ISBN |
92-9168-123-7 |
Medium |
|
|
| |
Area |
|
Expedition |
|
Conference |
|
|
| |
Notes |
|
Approved |
no |
|
| |
Call Number |
50-13430 |
Serial |
50465 |
|
| Permanent link to this record |
| |
|
| |
|
Author |
European Monitoring Centre for Drugs and Drug Addiction |
|
| |
Title |
Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs |
Type |
Report |
| |
Year |
2002 |
Publication |
|
Abbreviated Journal |
|
|
| |
Volume |
|
Issue |
|
Pages |
92 |
|
| |
Keywords |
amphetamines; gamma-hydroxybutyric acid; monitoring; risk assessment; designer drug; research chemical; report; Europe |
|
| |
Abstract |
Since the mid-1990s, GHB – widely used in human and veterinary medicine for 30 years – has been surfacing as a recreational drug. Some EU countries have reported worries over GHB’s surreptitious use in sexual assaults. Although the extent of this is unknown, the EMCDDA and its risk-assessment partners are recommending that Member States consider the role of GHB and other drugs in this area. The risk-assessment exercise was carried out in 2000 in the framework of the Joint action on new synthetic drugs. In March 2001, the EU Justice and Home Affairs Council adopted formal conclusions that Member States should monitor this drug closely. This publication records the findings and conclusions of the exercise. Among others, it draws together the various elements used to assess the substance including: the final risk-assessment report; contributions from Europol and the European Agency for the Evaluation of Medicinal Products; a review of pharmacotoxicological data; epidemiological evidence on the associated public-health risks and sociological and criminological evidence. |
|
| |
Address |
|
|
| |
Corporate Author |
|
Thesis |
|
|
| |
Publisher |
Office for Official Publications of the European Communities |
Place of Publication |
Luxembourg |
Editor |
|
|
| |
Language |
English |
Summary Language |
|
Original Title |
|
|
| |
Series Editor |
|
Series Title |
Risk assessments |
Abbreviated Series Title |
|
|
| |
Series Volume |
|
Series Issue |
|
Edition |
|
|
| |
ISSN |
1725-4485 |
ISBN |
92-9168-122-9 |
Medium |
|
|
| |
Area |
|
Expedition |
|
Conference |
|
|
| |
Notes |
|
Approved |
no |
|
| |
Call Number |
50-13431 |
Serial |
50466 |
|
| Permanent link to this record |
| |
|
| |
|
Author |
Health Protection Agency; Scottish Centre for Infection and Environmental Health; National Public Health Service for Wales; Communicable Disease Surveillance Centre Northern Ireland; Centre for Research on Drugs and Health Behaviour; Unlinked Anonymous Surveys Steering Group |
|
| |
Title |
Shooting up : infections among injecting drug users in the United Kingdom 2003 |
Type |
Report |
| |
Year |
2004 |
Publication |
|
Abbreviated Journal |
|
|
| |
Volume |
|
Issue |
|
Pages |
24 |
|
| |
Keywords |
Intravenous drug user; infection; HIV infection; viral hepatitis; hepatitis C; hepatitis B; hepatitis A; needle sharing; personal hygiene; United Kingdom |
|
| |
Abstract |
|
|
| |
Address |
|
|
| |
Corporate Author |
|
Thesis |
|
|
| |
Publisher |
Health Protection Agency (HPA) |
Place of Publication |
London |
Editor |
|
|
| |
Language |
English |
Summary Language |
|
Original Title |
|
|
| |
Series Editor |
|
Series Title |
|
Abbreviated Series Title |
|
|
| |
Series Volume |
|
Series Issue |
|
Edition |
|
|
| |
ISSN |
|
ISBN |
|
Medium |
|
|
| |
Area |
|
Expedition |
|
Conference |
|
|
| |
Notes |
|
Approved |
no |
|
| |
Call Number |
50-j |
Serial |
50467 |
|
| Permanent link to this record |
| |
|
| |
|
Author |
Health Protection Agency; Health Protection Scotland; National Public Health Service for Wales; Communicable Disease Surveillance Centre Northern Ireland; Centre for Research on Drugs and Health Behaviour; Unlinked Anonymous Surveys Steering Group |
|
| |
Title |
Shooting up : infections among injecting drug users in the United Kingdom 2004 |
Type |
Report |
| |
Year |
2005 |
Publication |
|
Abbreviated Journal |
|
|
| |
Volume |
|
Issue |
|
Pages |
24 |
|
| |
Keywords |
intravenous drug user; infection; HIV infection; viral hepatitis; hepatitis C; vaccination; hepatitis A; hepatitis B; needle sharing; personal hygiene; crack cocaine; United Kingdom |
|
| |
Abstract |
|
|
| |
Address |
|
|
| |
Corporate Author |
|
Thesis |
|
|
| |
Publisher |
Health Protection Agency (HPA) |
Place of Publication |
London |
Editor |
|
|
| |
Language |
English |
Summary Language |
|
Original Title |
|
|
| |
Series Editor |
|
Series Title |
|
Abbreviated Series Title |
|
|
| |
Series Volume |
|
Series Issue |
|
Edition |
|
|
| |
ISSN |
|
ISBN |
|
Medium |
|
|
| |
Area |
|
Expedition |
|
Conference |
|
|
| |
Notes |
|
Approved |
no |
|
| |
Call Number |
50-k |
Serial |
50468 |
|
| Permanent link to this record |
| |
|
| |
|
Author |
Health Protection Agency; Health Protection Scotland; National Public Health Service for Wales; Communicable Disease Surveillance Centre Northern Ireland; Centre for Research on Drugs and Health Behaviour; Unlinked Anonymous Surveys Steering Group |
|
| |
Title |
Shooting up : infections among injecting drug users in the United Kingdom 2005 |
Type |
Report |
| |
Year |
2006 |
Publication |
|
Abbreviated Journal |
|
|
| |
Volume |
|
Issue |
|
Pages |
24 |
|
| |
Keywords |
intravenous drug user; infection; HIV infection; viral hepatitis; hepatitis C; vaccination; hepatitis B; needle sharing; personal hygiene; crack cocaine; United Kingdom |
|
| |
Abstract |
Key findings: HIV: The prevalence of HIV infection among injecting drug users (IDUs) in England and Wales has increased in recent years. Overall, around one in 50 IDUs are now infected, which is still low compared to many other countries. The prevalence remains elevated among IDUs in London with around one in 25 HIV infected. The recent increase in HIV prevalence has been greatest elsewhere in England and Wales, where the prevalence has risen from around one in 400 in 2003 to about one in 65 in 2005. Hepatitis C: Overall, approaching one in two IDUs in the UK have been infected with hepatitis C, which is also low compared to many other countries. However, there are marked regional variations in hepatitis C prevalence within the UK, with the low prevalences found in some areas suggesting that hepatitis C infection is not an inevitable consequence of injecting drug use. Surveillance and research data also indicate that the overall prevalence of hepatitis C infection among IDUs has probably increased in recent years and that levels of hepatitis C transmission remain elevated. Voluntary confidential diagnostic testing: Uptake of testing for hepatitis C among IDUs in contact with drug services has increased in recent years. It is estimated, however, that almost half of those IDUs with hepatitis C in contact with these services still remain unaware of their infection. There will also be substantial numbers of current and former IDUs who are not in contact with services who will be unaware they have hepatitis C. Whilst most IDUs in contact with services report having had a test for HIV at some point, less than half of those with HIV are aware of their infection. There is therefore a need to improve the provision of voluntary confidential testing services for both hepatitis C and HIV. Vaccination: The proportion of IDUs reporting uptake of hepatitis B vaccination has increased markedly in recent years, with the prison vaccination programmes being a major factor in this increase. However, the transmission of hepatitis B continues among IDUs. There is a particular need to improve the provision of vaccinations to IDUs through needle exchange services, including the provision of the vaccines against hepatitis A and tetanus as well as that against hepatitis B. In England, the National Treatment Agency for Substance Misuse (NTA) is developing performance monitoring for the provision of vaccination by services for drug users. Bacterial infections: The ongoing occurrence of wound botulism cases indicates that the environmental contamination of heroin with bacterial spores remains a problem. There are also continuing problems with injecting site infections associated with methicillin resistant Staphylococcus aureus and severe group A streptococcal infection. Behaviours: Levels of reported needle and syringe sharing increased in the late 1990s, and since then have remained elevated with over a quarter of IDUs reporting sharing in the previous month. The sharing of other injecting equipment is more common. There are also indications that injecting into the groin (femoral vein) may be becoming more common. It is also apparent that there are a variety of individual and environmental factors that may affect injecting behaviour and hygiene, and that the effects on risk of factors such as homelessness, the injecting environment, and drugs injected need further investigation. In particular the role of crack-cocaine use, which has become more widespread, is a cause for concern. |
|
| |
Address |
|
|
| |
Corporate Author |
|
Thesis |
|
|
| |
Publisher |
Health Protection Agency (HPA) |
Place of Publication |
London |
Editor |
|
|
| |
Language |
English |
Summary Language |
|
Original Title |
|
|
| |
Series Editor |
|
Series Title |
|
Abbreviated Series Title |
|
|
| |
Series Volume |
|
Series Issue |
|
Edition |
|
|
| |
ISSN |
|
ISBN |
|
Medium |
|
|
| |
Area |
|
Expedition |
|
Conference |
|
|
| |
Notes |
|
Approved |
no |
|
| |
Call Number |
50-l |
Serial |
50469 |
|
| Permanent link to this record |
| |
|
| |
|
Author |
Federal Office of Public Health (ed) |
|
| |
Title |
Heroin-assisted treatment (HAT) in 2002 |
Type |
Book Whole |
| |
Year |
2003 |
Publication |
|
Abbreviated Journal |
|
|
| |
Volume |
|
Issue |
|
Pages |
18 |
|
| |
Keywords |
treatment and maintenance; drug substitution therapy; heroin; heroin-assisted treatment; annual report; Switzerland |
|
| |
Abstract |
|
|
| |
Address |
|
|
| |
Corporate Author |
|
Thesis |
|
|
| |
Publisher |
Federal Office of Public Health (FOPH) |
Place of Publication |
Berne |
Editor |
Federal Office of Public Health |
|
| |
Language |
English |
Summary Language |
|
Original Title |
|
|
| |
Series Editor |
|
Series Title |
|
Abbreviated Series Title |
|
|
| |
Series Volume |
|
Series Issue |
|
Edition |
|
|
| |
ISSN |
|
ISBN |
|
Medium |
|
|
| |
Area |
|
Expedition |
|
Conference |
|
|
| |
Notes |
Auch auf Deutsch vorhanden; aussi disponible en français |
Approved |
no |
|
| |
Call Number |
50-y |
Serial |
50482 |
|
| Permanent link to this record |
| |
|
| |
|
Author |
Osservatorio europeo delle droghe e delle tossicodipendenze |
|
| |
Title |
Relazione annuale 2007 : evoluzione del fenomeno della droga in Europa |
Type |
Report |
| |
Year |
2007 |
Publication |
|
Abbreviated Journal |
|
|
| |
Volume |
|
Issue |
|
Pages |
93 |
|
| |
Keywords |
AOD public policy strategy; public policy on illicit drugs; other drug laws; cannabis; MDMA; ecstasy; LSD; cocaine; crack cocaine; intravenous injection; opioids in any form; piperazine; ketamine; gamma-hydroxybutyric acid; communicable disease; AODR mortality; Europe; annual report |
|
| |
Abstract |
The report on the state of the drugs problem in Europe presents the EMCDDA’s yearly overview of the drug phenomenon. This is an essential reference book for policy-makers, specialists and practitioners in the drugs field or indeed anyone seeking the latest findings on drugs in Europe. Published every autumn, the report contains non-confidential data supported by an extensive range of figures. |
|
| |
Address |
|
|
| |
Corporate Author |
|
Thesis |
|
|
| |
Publisher |
Ufficio delle pubblicazioni ufficiali delle Comunità europee |
Place of Publication |
Lussemburgo |
Editor |
|
|
| |
Language |
Italian |
Summary Language |
|
Original Title |
|
|
| |
Series Editor |
|
Series Title |
Relazione annuale |
Abbreviated Series Title |
|
|
| |
Series Volume |
|
Series Issue |
|
Edition |
|
|
| |
ISSN |
1609-6169 |
ISBN |
978-92-9168-294-2 |
Medium |
|
|
| |
Area |
|
Expedition |
|
Conference |
|
|
| |
Notes |
Auch auf Deutsch vorhanden: 13.02-036; aussi disponible en français: 50-11651; also available in English: 50-11653 |
Approved |
no |
|
| |
Call Number |
50-z |
Serial |
50483 |
|
| Permanent link to this record |
| |
|
| |
|
Author |
Groupement romand d'études des addictions |
|
| |
Title |
Rapport annuel 2007 |
Type |
Report |
| |
Year |
2008 |
Publication |
|
Abbreviated Journal |
|
|
| |
Volume |
|
Issue |
|
Pages |
13 |
|
| |
Keywords |
financial statement; Switzerland; regional area; Yverdon-les-Bains; Groupement romand d’études des addictions (body); annual report |
|
| |
Abstract |
|
|
| |
Address |
|
|
| |
Corporate Author |
|
Thesis |
|
|
| |
Publisher |
Groupement romand d'études des addictions (GREA) |
Place of Publication |
Yverdon-les-Bains |
Editor |
|
|
| |
Language |
French |
Summary Language |
|
Original Title |
|
|
| |
Series Editor |
|
Series Title |
|
Abbreviated Series Title |
|
|
| |
Series Volume |
|
Series Issue |
|
Edition |
|
|
| |
ISSN |
|
ISBN |
|
Medium |
|
|
| |
Area |
|
Expedition |
|
Conference |
|
|
| |
Notes |
|
Approved |
no |
|
| |
Call Number |
50-ad |
Serial |
50487 |
|
| Permanent link to this record |
